Key facts
- Eli Lilly has halved its planned investment in Germany.
- The investment has been reduced from €800 million to €400 million.
- The decision is linked to Germany's healthcare reforms.
- Eli Lilly CEO David Ricks cited concerns about patent protection in Germany.
Eli Lilly and Company has significantly scaled back its investment plans in Germany. The pharmaceutical giant will now invest €400 million in its German operations, a decrease from the previously planned €800 million. CEO David Ricks announced plans to halve the company's investment due to concerns about patent protection in the country. This decision comes in response to Germany's ongoing healthcare reforms, which appear to have altered the economic or regulatory outlook for Eli Lilly's business within Germany. The company's move signals a potential impact of these reforms on foreign investment within the German healthcare sector.